Thoracic Surgery Division, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio.
Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, Ohio.
Ann Thorac Surg. 2020 Sep;110(3):1012-1022. doi: 10.1016/j.athoracsur.2020.03.048. Epub 2020 Apr 23.
Tracheal cancer (TC) is a rare disease, and surgical treatment requires a high level of expertise. We sought to determine the treatment patterns and surgical outcomes of TC in the United States.
The National Cancer Database was queried for all cases of primary invasive TC without distant metastatic disease between 2004 and 2015. Primary surgical treatment and outcomes were analyzed. Factors associated with utilization of surgery and overall survival were tested using regression analysis.
Of 1379 identified TC patients, 338 patients (25%) were treated surgically. Among resected patients, most had adenoid cystic (48%) or squamous cell (28%) carcinoma. Median length of hospital stay after resection was 7 days (interquartile range, 3-8), and 30-day mortality was 1.4%. Most nonsurgically managed patients underwent radiation (63%). Factors associated with surgical resection were younger age, higher education level, tumor size, and adenoid cystic histology. On multivariate analysis patients were also more likely to undergo surgery if they traveled a farther distance for treatment (>45 km; odds ratio, 1.53; 95% confidence interval, 1.09-2.13) or were treated at academic centers (odds ratio, 1.68; 95% confidence interval, 1.25-2.26). Five-year overall survival was 71% after resection, 39% after surgical debulking, and 31% without surgery (P < .001).
National surgical outcomes for resection of TC demonstrate low perioperative mortality and excellent long-term prognosis. However, few nonmetastatic TC patients underwent surgery, indicating disparities in access to optimal surgical care and variability in practice patterns at a national level.
气管癌(TC)是一种罕见疾病,其外科治疗需要高度的专业知识。我们旨在确定美国 TC 的治疗模式和手术结果。
2004 年至 2015 年期间,国家癌症数据库对所有无远处转移疾病的原发性浸润性 TC 病例进行了查询。分析了主要的手术治疗和结果。使用回归分析测试了与手术利用和总体生存率相关的因素。
在 1379 例确定的 TC 患者中,有 338 例(25%)接受了手术治疗。在接受切除的患者中,大多数患有腺样囊性(48%)或鳞状细胞(28%)癌。切除后住院中位数为 7 天(四分位距,3-8),30 天死亡率为 1.4%。大多数非手术治疗的患者接受了放疗(63%)。与手术切除相关的因素包括年龄较小、教育程度较高、肿瘤大小和腺样囊性组织学。多变量分析显示,患者如果治疗距离较远(>45 公里;优势比,1.53;95%置信区间,1.09-2.13)或在学术中心治疗(优势比,1.68;95%置信区间,1.25-2.26),则更有可能进行手术。切除后的 5 年总生存率为 71%,手术减瘤后的生存率为 39%,未手术的生存率为 31%(P<.001)。
全国范围内 TC 切除的手术结果显示围手术期死亡率低,长期预后良好。然而,只有少数非转移性 TC 患者接受了手术,这表明在获得最佳手术治疗方面存在差异,并且在全国范围内手术模式存在差异。